BUZZ-Australia's Cynata Therapeutics leaps as clinical trial progresses
Reuters
Dec 15, 2025
BUZZ-Australia's <a href="https://laohu8.com/S/CYP.AU">Cynata Therapeutics</a> leaps as clinical trial progresses
** Shares of Cynata TherapeuticsCYP.AX rise as much as 7.6% to A$0.285, their highest level since December 1
** Stock set for its strongest trading session in over a week, if current trends hold
** Stem cell and regenerative medicine maker says 65 patients have been enrolled in its Phase 2 clinical trial of CYP-001 in adults diagnosed with acute graft versus host disease (aGvHD)
** aGvHD is a life-threatening complication where donor’s immune cells attack recipient's tissues
** Co says CYP-001 is designed to modulate immune system and improve both response rates and survival outcomes in aGvHD
** Stock up 18.6% YTD, including session's moves
(Reporting by Aamir Sheik Khalid in Bengaluru)
((Aamir.SheikKhalid@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.